A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-23. Anything still debated is marked as such rather than presented as settled.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Following World War II, Britain controlled both British Somaliland and Italian Somaliland. During the 1945 Potsdam Conference, the United Nations granted Italy Italian Somaliland, on the condition that Somalia achieve independence within ten years, due to pressure from Somali organisations. British Somaliland remained a protectorate of Britain until 1960. The trusteeship gave Somalis the opportunity to gain experience in Western political education and self-government. These were advantages that British Somaliland lacked, as it was to be incorporated into the new Somali state. In the 1950s British officials attempted, to improve various administrative development efforts. However, the protectorate stagnated administratively. The disparity between the two territories would cause difficulties integrating. In 1948, pressured by their allies and disappointing the Somalis, the British returned the Haud, an important Somali grazing area, and the Somali Region to Ethiopia, based on a treaty they signed in 1897 in which the British ceded Somali territory to the Ethiopian Emperor.
Another function of this coenzyme in cell signaling is as a precursor of cyclic ADP-ribose, which is produced from NAD+ by ADP-ribosyl cyclases, as part of a second messenger system. This molecule acts in calcium signaling by releasing calcium from intracellular stores. It does this by binding to and opening a class of calcium channels called ryanodine receptors, which are located in the membranes of organelles, such as the endoplasmic reticulum, and inducing the activation of the transcription factor NAFC3 NAD+ is also consumed by different NAD+-consuming enzymes, such as CD38, CD157, PARPs and the NAD-dependent deacetylases (sirtuins, such as Sir2.). These enzymes act by transferring an acetyl group from their substrate protein to the ADP-ribose moiety of NAD+; this cleaves the coenzyme and releases nicotinamide and O-acetyl-ADP-ribose. The sirtuins mainly seem to be involved in regulating transcription through deacetylating histones and altering nucleosome structure. However, non-histone proteins can be deacetylated by sirtuins as well. These activities of sirtuins are particularly interesting because of their importance in the regulation of aging. Other NAD-dependent enzymes include bacterial DNA ligases, which join two DNA ends by using NAD+ as a substrate to donate an adenosine monophosphate (AMP) moiety to the 5' phosphate of one DNA end. This intermediate is then attacked by the 3' hydroxyl group of the other DNA end, forming a new phosphodiester bond. This contrasts with eukaryotic DNA ligases, which use ATP to form the DNA-AMP intermediate. Li et al.
There is no evidence to suggest that MMF is a specific illness. MMF is a lesion containing aluminium salts, identified by histopathological examination, found at the site of previous vaccination with an aluminium-containing vaccine.
== Centenarians in antiquity == While the number of centenarians per capita was much lower in ancient times than today, the data suggest that they were not unheard of. Estimates of life expectancy in antiquity are far lower than modern values largely due to the far greater incidence of deaths in infancy or childhood, though adult mortality was also considerably greater than today. The assumption of what constitutes "old age", or being "elderly", at least, seems to have remained unchanged since antiquity, the line being generally drawn at either sixty or sixty-five years; Psalm 90:10 in the Hebrew Bible appears to give seventy to eighty years as the natural life expectancy of a person surviving into old age, "The years of our life are seventy, or even by reason of strength eighty". A survey of the lifespans of male individuals with entries in the Oxford Classical Dictionary (i.e., a sample pre-selected to include those who lived long enough to attain historical notability) found a median lifespan of 72 years, and a range of 32 to 107 years, for 128 individuals born before 100 BC (though the same study found a median lifespan of 66 years for 100 individuals born after 100 BC but no later than 602 AD); by comparison, male individuals listed in Chambers Biographical Dictionary who died between 1900 and 1949 had a median lifespan of 71.5 years, with a range between 29 and 105 years. But as indicated above, far fewer in antiquity survived even from early adulthood to such advanced age – probably under a fifth, compared to a global average of two-thirds today.
In the example of a snake bite, the use of anti-venom halts the spread of toxins whilst receiving antibiotics to impede infection. Even after the initial cause of the necrosis has been halted, the necrotic tissue will remain in the body. The body's immune response to apoptosis, which involves the automatic breaking down and recycling of cellular material, is not triggered by necrotic cell death due to the apoptotic pathway being disabled.
Sources: en.wikipedia.org
Through studying the transport of biogenic substances in the Tatar Strait in the Sea of Japan, a Russian team noted that biogenic substances can enter the marine environment due to input from either external sources, transport inside the water masses, or development by metabolic processes within the water. They can likewise be expended due to biotransformation processes, or biomass formation by microorganisms. In this study the biogenic substance concentrations, transformation frequency, and turnover were all highest in the upper layer of the water. Additionally, in different regions of the strait the biogenic substances with the highest annual transfer were constant. These were O2, DOC, and DISi, which are normally found in large concentrations in natural water. The biogenic substances that tend to have lower input through the external boundaries of the strait and therefore least transfer were mineral and detrital components of N and P. These same substances take active part in biotransformation processes in the marine environment and have lower annual output as well.
There is still much ongoing differential (DNA sequence based) comparison research that is trying to separate out the simplest forms of chordates. As some lineages that lack a backbone or notochord might have lost these structures over time, this complicates the classification of chordates. Some chordate lineages may only be identified by DNA analysis as there is no physical trace of any chordate-like structures. Attempts to work out the evolutionary relationships of the chordates have produced several hypotheses. The current consensus is that chordates are monophyletic (meaning, all chordates are descend from a single, common ancestor, which can be considered a chordate) and that the vertebrates' nearest relatives are tunicates. In 2016, identification of two conserved signature indels (CSIs) in the proteins cyclophilin-like protein and mitochondrial inner membrane protease ATP23, which are exclusively shared by all vertebrates, tunicates and cephalochordates also provided strong evidence of the monophyly of Chordata. All of the earliest chordate fossils have been found in the Early Cambrian Chengjiang fauna, and include three species that are regarded as fish, and hence vertebrates. Because the fossil record of early chordates is poor, only molecular phylogenetics offers a reasonable prospect of dating their emergence. However, the use of molecular phylogenetics for dating evolutionary transitions is controversial. It has proven difficult to produce a detailed classification within the living chordates.
Tertomotide (GV1001, EARPALLTSRLRFIPK) is a 16-amino acid peptide based on the 616‑626 position fragment of human telomerase reverse transcriptase protein (hTERT). It was originally developed as a possible subunit vaccine for various types of cancer, as it can trigger immune attack against cancer cells which overexpress telomerase, a common mutation found in malignant tumors. However, it does not block telomerase activity in healthy tissue and has been found to produce various useful activities in its own right including antiviral, antiinflammatory and antidepressant effects, and has been trialled for numerous other medical applications including Alzheimer's disease as well as its original role in the treatment of cancer.
== Contraindications == Acute intermittent porphyria, hypersensitivity to any barbiturate, prior dependence on barbiturates, severe respiratory insufficiency (as with chronic obstructive pulmonary disease), severe liver failure, pregnancy, and breastfeeding are contraindications for phenobarbital use.
== Lineage == Constituted 5 July 1942 in the Army of the United States as the 2d Company, 1st Battalion, First Regiment, 1st Special Service Force, a combined Canadian-American organization Activated on 9 July 1942 at Fort William Henry Harrison, Montana Disbanded on 6 January 1945 in France Reconstituted on 15 April 1960 in the Regular Army; concurrently consolidated with Company B, 1st Ranger Infantry Battalion (activated 19 June 1942), and consolidated unit redesignated as Headquarters and Headquarters Company, 1st Special Forces Group, 1st Special Forces Consolidated on 30 September 1960 with Headquarters and Headquarters Company, 1st Special Forces Group (constituted 14 June 1957 in the Regular Army and activated 24 June 1957 in Japan), and the consolidated unit was designated as Headquarters and Headquarters Company, 1st Special Forces Group, 1st Special Forces (organic units concurrently constituted and activated 4 October 1960) Group inactivated 30 June 1974 at Fort Bragg, North Carolina Activated 1 September 1984 at Fort Lewis, Washington (Former Company B, 1st Ranger Infantry Battalion, withdrawn 3 February 1986, consolidated with Company N, 75th Infantry, and consolidated unit redesignated as Company N, 75th Ranger Regiment – hereafter separate lineage) Redesignated 1 October 2005 as the 1st Special Forces Group, 1st Special Forces Regiment
Sources: en.wikipedia.org
The importation of mephedrone into the UK was banned on 29 March 2010. The next day, the ACMD in the UK published a report on the cathinones, including mephedrone, and recommended they be classified as Class B drugs. On 7 April 2010, the Misuse of Drugs Act 1971 (Amendment) Order 2010 was passed by parliament, making mephedrone and other substituted cathinones, Class B drugs from 16 April 2010. Prior to the ban taking effect, mephedrone was not covered by the Misuse of Drugs Act 1971. It was, though, an offence under the Medicines Act to sell it for human consumption, so it was often sold as "plant food" or "bath salts", although it has no use as these products; this, too, was possibly illegal under the Trade Descriptions Act 1968. In the US, similar descriptions have been used to describe mephedrone, as well as methylenedioxypyrovalerone (MDPV). In May 2010, the Republic of Ireland made mephedrone illegal, followed by Belgium, Italy, Lithuania, France and Norway in June and Russia in July. In August 2010, Austria and Poland made it illegal and China announced it would be illegal as of 1 September 2010. Mephedrone had been reported to be used in Singapore in February 2010, but it was made illegal in November 2010. In December 2010, following the advice of the EMCDDA, mephedrone was made illegal throughout the EU, a move Switzerland also made shortly afterwards. Countries which have not already banned it, such as the Netherlands, Greece and Portugal, will need to change legislation to comply with the EU ruling.
== Experimental chemistry == Unambiguous determination of the chemical characteristics of darmstadtium has yet to have been established due to the short half-lives of darmstadtium isotopes and a limited number of likely volatile compounds that could be studied on a very small scale. One of the few darmstadtium compounds that are likely to be sufficiently volatile is darmstadtium hexafluoride (DsF6), as its lighter homologue platinum hexafluoride (PtF6) is volatile above 60 °C and therefore the analogous compound of darmstadtium might also be sufficiently volatile; a volatile octafluoride (DsF8) might also be possible. For chemical studies to be carried out on a transactinide, at least four atoms must be produced, the half-life of the isotope used must be at least 1 second, and the rate of production must be at least one atom per week. Even though the half-life of 281Ds, the most stable confirmed darmstadtium isotope, is 14 seconds, long enough to perform chemical studies, another obstacle is the need to increase the rate of production of darmstadtium isotopes and allow experiments to carry on for weeks or months so that statistically significant results can be obtained. Separation and detection must be carried out continuously to separate out the darmstadtium isotopes and have automated systems experiment on the gas-phase and solution chemistry of darmstadtium, as the yields for heavier elements are predicted to be smaller than those for lighter elements; some of the separation techniques used for bohrium and hassium could be reused.
When levels of somatotropin are low in the body, a physician may prescribe human growth hormone as a drug. Deficiency in somatotrope secretion before puberty or before the end of new bone tissue growth, can lead to pituitary dwarfism. When growth hormone is deficient, blood sugar is low because insulin is not opposed by normal amount of growth hormone.
This low dose of radioiodine is typically tolerated by individuals otherwise allergic to iodine (such as those unable to tolerate contrast mediums containing larger doses of iodine, such as used in CT scan, intravenous pyelogram (IVP), and similar imaging diagnostic procedures). Excess radioiodine that does not get absorbed into the thyroid gland is eliminated by the body in urine. Some people with hyperthyroidism may experience a slight allergic reaction to the diagnostic radioiodine and may be given an antihistamine. The person returns 24 hours later to have the level of radioiodine "uptake" (absorbed by the thyroid gland) measured by a device with a metal bar placed against the neck, which measures the radioactivity emitted from the thyroid. This test takes about 4 minutes while the uptake % (i.e., percentage) is accumulated (calculated) by the machine software. A scan is also performed, wherein images (typically a center, left, and right angle) are taken of the contrasted thyroid gland with a gamma camera; a radiologist will read and prepare a report indicating the uptake % and comments after examining the images. People with hyperthyroidism will typically "take up" higher-than-normal levels of radioiodine. Normal ranges for RAI uptake are from 10 to 30%. In addition to testing the TSH levels, many doctors test for T3, Free T3, T4, and/or Free T4 for more detailed results. Free T4 is unbound to any protein in the blood.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.